Summary
Nebivolol (Nomexor®) is a third generation, vasodilating beta-blocker with a high β1-adrenoceptor selectivity. Nebivolol acts as an agonist at the β3 adrenoceptor as well as the estrogen receptor thereby releasing nitric oxide in blood vessels via eNOS. Pleiotropic effects of nebivolol furthermore include a positive influence on cholesterol and triglycerides and a decrease in thrombocyte activity. Nebivolol is recommended in the guidelines of the European cardiac society (ESC) for patients with metabolic syndrome. Nebivolol's main properties in combination with its broad range of beneficial pleiotropic effects allow it to be clearly distinguished from other second and third generation beta-blockers.
Zusammenfassung
Nebivolol (Nomexor®) ist ein Adrenoceptor-Antagonist der 3. Generation mit einer ausgeprägten β1-Adrenozeptorselektivität (Kardioselektivität). Zusätzlich zeichnet sich der Betablocker Nebivolol durch seine vasodilatatorische Aktivität aus. Durch eine agonistische Wirkung von Nebivolol am β3-Adrenozeptor und am Östrogenrezeptor kommt es über die eNOS zur Freisetzung von Stickstoffmonoxid (NO) in den Gefäßen. Auch die positive Beeinflussung des Lipidprofils und das Vermindern der Plättchenaggregation sind als positive Nebenwirkungen für das Gesamtbild dieses Arzneistoffes verantwortlich. Darüber hinaus spiegeln die aktuellen Leitlinien der ESC dies wieder, indem sie auf die Vorteile von Nebivolol beim Patienten mit metabolischem Syndrom explizit hinweisen. Diese zusätzlichen positiven Effekte von Nebivolol in Kombination mit der Hauptwirkung sind eine wichtige Unterscheidung zu anderen Betablockern der 2. und 3. Generation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther, 28: 179–186, 2003
Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens, 18(12 Pt 2): 169S–176S, 2005
Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl, 1: 2–16, 2004
Brehm BR, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol, 36(5 Suppl 1): S401–S403, 2000
Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol, 51: 259–264, 1996
Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frerart F, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation, 112: 1198–1205, 2005
Kakoki M, Hirata Y, Hayakawa H, Nishimatsu H, Suzuki Y, Nagata D, et al. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension, 33(1 Pt 2): 467–471, 1999
Brehm BR, Wolf SC, Bertsch D, Klaussner M, Wesselborg S, Schuler S, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res, 49: 430–439, 2001
Sessa WC. eNOS at a glance. J Cell Sci, 117(Pt 12): 2427–2429, 2004
Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest, 91: 2546–2551, 1993
Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol, 30: 535–560, 1990
Cominacini L, Fratta Pasini A, Garbin U, Nava C, Davoli A, Criscuoli M, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol, 42: 1838–1844, 2003
Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens, 23: 589–596, 2005
von Fallois J, Faulhaber HD. Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study. Fortschr Med Orig, 118(Suppl 2): 77–82, 2000
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 28: 1462–1536, 2007
Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens, 24: 1397–1403, 2006
Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens, 24: 591–596, 2006
Rosei AR, Rizzoni D. Metabolic Profile of Nebivolol, a ß-Adrenoceptor Antagonist with Unique Characteristics. Drugs, 67: 1097–1107, 2007
von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA, 92: 1137–1141, 1995
Falciani M, Rinaldi B, D'Agostino B, Mazzeo F, Rossi S, Nobili B, et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol, 38: 922–929, 2001
Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl, 2: 35–40, 2003
Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol, 92: 344–348, 2003
Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail, 7: 631–639, 2005
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J, 26: 215–225, 2005
Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens, 26: 351–356, 2008
Matthys H, Giebelhaus V, von Fallois J. Nebivolol (nebilet) a beta blocker of the third generation – also for patients with obstructive lung diseases?. Z Kardiol, 90: 760–765, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ladage, D., Reidenbach, C., Lichtenthal, A. et al. Betablocker der 3. Generation: Stand der Forschung zu den Betablockern mit vasodilatierenden Zusatzeigenschaften. Wien Med Wochenschr 159, 211–218 (2009). https://doi.org/10.1007/s10354-009-0650-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-009-0650-3